View Cancer Clinical Trials
A Pilot Study for Evaluating the Neural Substrates of Cognitive impairments and movement-related fatigue in women undergoing adjuvant chemotherapy (CARES)
- To determine the feasibility of cognitive testing, TMS and rsF-MRI pre and post adjuvant chemotherapy
- To determine if cognitive deficits are related to changes in fc and white matter damage in women who have received adjuvant chemotherapy for breast cancer
- To determine if fatigue is related to excitability of motor cortices, white matter damage and fc in women treated with adjuvant chemotherapy for breast cancer Subjective (Brief Fatigue Index or Inventory, BFI)
- Females (≥ 18 years of age) with histologically proven breast cancer without metastases, who are disease-free after surgery and/or radiation to the breast
- These patients will be anticipated to undergo adjuvant chemotherapy for no less than 4 cycles and have an ECOG performance score 0 to 2.
- Their hemoglobin levels should be ≥ 9 gram/dL.
- Only receiving hormone therapy,
- Have breast tissue expander
- Diagnosed with heart failure (NYHA class 3 and 4)
- Have metastatic disease excluding axilla and treated for curative intent
- History of stroke, myasthenia gravis, multiple sclerosis, polyneuropathy, conditions as pregnancy or breast feeding
- Any contraindications to TMS^32 or MRI
- ECOG performance score greater than 2
- Hemoglobin levels should be < 9 gram/dL
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2014 Cleveland Clinic. All rights reserved.